On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

Daiichi Sankyo's new a-fib drug heads toward FDA approval and a crowded market

A panel of FDA advisers voted in favor of approving Daiichi Sankyo's irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving the company's odds of finally launching the drug in the U.S.

Big Pharma backs EU antibiotic R&D plan, Pfizer prompts Karo cuts, Advent closes £146M fund

In this week's EuroBiotech Report, a who's who of Big Pharma companies joined a European public-private consortium to develop and test new economic models of antibiotic R&D with the goal of making antibiotic R&D economically attractive again. And more.

Cortendo to raise $11 mln in private placement

Cortendo has agreed to a private placement with HealthCap, the Third Swedish National Pension Fund, Storebrand and Arctic Fund Management. According to terms of the transaction, Cortendo will raise...

Chris Viehbacher leaving Sanofi without a U.S.-style windfall

For the now-former chief of Sanofi, Chris Viehbacher, there's plenty of money for a cushion, but it won't be nearly as plump as the packages granted to his counterparts in the U.S.

FibroGen dials up a $155M IPO; AstraZeneca partners with University of Manchester;

@FierceBiotech: ICYMI earlier this month, check out this year's Women in Biotech, featuring women at the top of their field. Feature | Follow @FierceBiotech @JohnCFierce: If $SNY's board did...

Chimerix Announces Commencement of Public Offering of Common Stock

DURHAM, N.C., Oct. 29, 2014 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it intends to...

Regulus Announces Pricing of Public Offering of Common Stock

LA JOLLA, Calif. -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company developing innovative medicines targeting microRNAs, today announced the pricing of an underwritten public...

Little Cortendo gains $11M for late-stage Cushing's study, hatches U.S. IPO plans

Cortendo is coming to America. Founded in Sweden, the little biotech has a new CEO who's building the executive team in the Philadelphia area. And he's dropping plans for a listing on the Oslo exchange in favor of a U.S. IPO after raising $11 million in bridge financing.

AstraZeneca wins another diabetes approval in a fast-crowding market

AstraZeneca won an FDA nod for a one-pill combination of its latest diabetes drug and the long-generic metformin, making it the second to market among a cadre of drugmakers developing similar cocktails.